Alpha-adrenergic agonist

Alpha adrenergic agonist
Drug class
Phenylephrine
Skeletal structor formula of phenylephrine, a common nasal decongestant
Class identifiers
UseDecongestant, Hypotension, Bradycardia, Hypothermia etc.
ATC codeN07
Biological targetAlpha adrenergic receptors of the α subtype
External links
MeSHD000316
Legal status
In Wikidata

Alpha-adrenergic agonists are a class of sympathomimetic agents that selectively stimulates alpha adrenergic receptors. The alpha-adrenergic receptor has two subclasses α1 and α2. Alpha 2 receptors are associated with sympatholytic properties. Alpha-adrenergic agonists have the opposite function of alpha blockers. Alpha adrenoreceptor ligands mimic the action of epinephrine and norepinephrine signaling in the heart, smooth muscle and central nervous system, with norepinephrine being the highest affinity. The activation of α1 stimulates the membrane bound enzyme phospholipase C, and activation of α2 inhibits the enzyme adenylate cyclase. Inactivation of adenylate cyclase in turn leads to the inactivation of the secondary messenger cyclic adenosine monophosphate and induces smooth muscle and blood vessel constriction.

Classes

Norepinephrine (noradrenaline)

Although complete selectivity between receptor agonism is rarely achieved, some agents have partial selectivity. NB: the inclusion of a drug in each category just indicates the activity of the drug at that receptor, not necessarily the selectivity of the drug (unless otherwise noted).

α1 agonist

Main article: Alpha-1 adrenergic receptor § agonist

α1 agonist: stimulates phospholipase C activity. (vasoconstriction and mydriasis; used as vasopressors, nasal decongestants and during eye exams). Selected examples are:

α2 agonist

Main article: Alpha-2 adrenergic receptor § Agonists

α2 agonist: inhibits adenylyl cyclase activity, reduces brainstem vasomotor center-mediated CNS activation; used as antihypertensive, sedative & treatment of opiate dependence and alcohol withdrawal symptoms). Selected examples are:

Nonspecific agonist

Nonspecific agonists act as agonists at both alpha-1 and alpha-2 receptors.

Undetermined/unsorted

The following agents are also listed as agonists by MeSH.[16]

Clinical significance

Alpha-adrenergic agonists, more specifically the auto receptors of alpha 2 neurons, are used in the treatment of glaucoma by decreasing the production of aqueous fluid by the ciliary bodies of the eye and also by increasing uveoscleral outflow. Medications such as clonidine and dexmedetomidine target pre-synaptic auto receptors, therefore leading to an overall decrease in norepinephrine which clinically can cause effects such as sedation, analgesia, lowering of blood pressure and bradycardia. There is also low quality evidence that they can reduce shivering post operatively.[17]

The reduction of the stress response caused by alpha 2 agonists were theorised to be beneficial peri operatively by reducing cardiac complications, however this has shown not to be clinically effective as there was no reduction in cardiac events or mortality but there was an increased incidence of hypotension and bradycardia.[18]

Alpha-2 adrenergic agonists are sometimes prescribed alone or in combination with stimulants to treat ADHD.[19]

See also

References

  1. ^ Declerck I, Himpens B, Droogmans G, Casteels R (September 1990). "The alpha 1-agonist phenylephrine inhibits voltage-gated Ca2(+)-channels in vascular smooth muscle cells of rabbit ear artery". Pflügers Arch. 417 (1): 117–9. doi:10.1007/BF00370780. PMID 1963492. S2CID 8074029.
  2. ^ MacLean MR, Thomson M, Hiley CR (June 1989). "Pressor effects of the alpha 2-adrenoceptor agonist B-HT 933 in anaesthetized and haemorrhagic rats: comparison with the haemodynamic effects of amidephrine". Br. J. Pharmacol. 97 (2): 419–32. doi:10.1111/j.1476-5381.1989.tb11969.x. PMC 1854522. PMID 2569342.
  3. ^ Sagvolden T (2006). "The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD)". Behav Brain Funct. 2: 41. doi:10.1186/1744-9081-2-41. PMC 1764416. PMID 17173664.
  4. ^ Atalik KE, Sahin AS, Doğan N (April 2000). "Interactions between phenylephrine, clonidine and xylazine in rat and rabbit aortas". Methods Find Exp Clin Pharmacol. 22 (3): 145–7. doi:10.1358/mf.2000.22.3.796096. PMID 10893695. S2CID 8218673.
  5. ^ Lemke KA (2004). "Perioperative use of selective alpha-2 agonists and antagonists in small animals". Can. Vet. J. 45 (6): 475–80. PMC 548630. PMID 15283516.
  6. ^ Crassous PA, Cardinaletti C, Carrieri A, Bruni B, Di Vaira M, Gentili F, Ghelfi F, Giannella M, Paris H, Piergentili A, Quaglia W, Schaak S, Vesprini C, Pigini M (August 2007). "Alpha2-adrenoreceptors profile modulation. 3.1 (R)-(+)-m-nitrobiphenyline, a new efficient and alpha2C-subtype selective agonist". Journal of Medicinal Chemistry. 50 (16): 3964–8. doi:10.1021/jm061487a. PMID 17630725.
  7. ^ Del Bello, Fabio; Mattioli, Laura; Ghelfi, Francesca; Giannella, Mario; Piergentili, Alessandro; Quaglia, Wilma; Cardinaletti, Claudia; Perfumi, Marina; Thomas, Russell J.; Zanelli, Ugo; Marchioro, Carla; Dal Cin, Michele; Pigini, Maria (11 November 2010). "Fruitful Adrenergic α2C-Agonism/α2A-Antagonism Combination to Prevent and Contrast Morphine Tolerance and Dependence". Journal of Medicinal Chemistry. 53 (21): 7825–7835. doi:10.1021/jm100977d. PMID 20925410.
  8. ^ Hsu, W. H. and Lu, Z.-X. (1984). Amitraz' induced delay of gastrointestinal transit in mice: Mediated by α2 adrenergic receptors. Drug Development Research, Volume 4 (6), 655- 680.
  9. ^ "Press Announcements - FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults". www.fda.gov. Retrieved 18 May 2018.
  10. ^ Sinclair MD (November 2003). "A review of the physiological effects of alpha2-agonists related to the clinical use of medetomidine in small animal practice". Can. Vet. J. 44 (11): 885–97. PMC 385445. PMID 14664351.
  11. ^ Haenisch, B.; Walstab, J.; Herberhold, S.; Bootz, F.; Tschaikin, M.; Ramseger, R.; Bönisch, H. (2009). "Alpha-adrenoceptor Agonistic Activity of Oxymetazoline and Xylometazoline". Fundamental & Clinical Pharmacology. 24 (6): 729–39. doi:10.1111/j.1472-8206.2009.00805.x. PMID 20030735. S2CID 25064699.
  12. ^ Westfall Thomas C, Westfall David P, "Chapter 6. Neurotransmission: The Autonomic and Somatic Motor Nervous Systems" (Chapter). Brunton LL, Lazo JS, Parker KL: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11e: "AccessMedicine | Anatomy and General Functions of the Autonomic and Somatic Motor Nervous Systems". Archived from the original on 2011-09-30. Retrieved 2015-01-24..
  13. ^ Horie, K; Obika, K; Foglar, R (1995). "Selectivity of the imidazoline α-adrenoceptor agonists (oxymetazoline and cirazoline) for human cloned α1-adrenoceptor subtypes". British Journal of Pharmacology. 116 (1): 1611–8. doi:10.1111/j.1476-5381.1995.tb16381.x. PMC 1908909. PMID 8564227.
  14. ^ Ruffolo, R. R. Jr.; Waddell, J. E. (1982). "Receptor interactions of imidazolines. IX. Cirazoline is an α1 adrenergic agonist and an α2 adrenergic antagonist". Journal of Pharmacology and Experimental Therapeutics. 222 (1): 29–36. PMID 6123592.
  15. ^ Shen, Howard (2008). Illustrated Pharmacology Memory Cards: PharMnemonics. Minireview. p. 4. ISBN 978-1-59541-101-3.
  16. ^ MeSH list of agents 82000316
  17. ^ Lewis, Sharon R; Nicholson, Amanda; Smith, Andrew F; Alderson, Phil (2015-08-10). "Alpha-2 adrenergic agonists for the prevention of shivering following general anaesthesia". Cochrane Database of Systematic Reviews. 2015 (8): CD011107. doi:10.1002/14651858.cd011107.pub2. ISSN 1465-1858. PMC 9221859. PMID 26256531.
  18. ^ Duncan, Dallas; Sankar, Ashwin; Beattie, W Scott; Wijeysundera, Duminda N (2018-03-06). "Alpha-2 adrenergic agonists for the prevention of cardiac complications among adults undergoing surgery". Cochrane Database of Systematic Reviews. 2018 (3): CD004126. doi:10.1002/14651858.cd004126.pub3. ISSN 1465-1858. PMC 6494272. PMID 29509957.
  19. ^ Coghill, David (2022). "The Benefits and Limitations of Stimulants in Treating ADHD". New Discoveries in the Behavioral Neuroscience of Attention-Deficit Hyperactivity Disorder. Current Topics in Behavioral Neurosciences. Vol. 57. Springer International Publishing. pp. 51–77. doi:10.1007/7854_2022_331. ISBN 978-3-031-11802-9. PMID 35503597.

External links